APA

Mürdter T. E., Schroth W., Bacchus-Gerybadze L., Winter S., Heinkele G., Simon W., Fasching P. A., Fehm T., Eichelbaum M., Schwab M. & Brauch H. (20110621). Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. : Clinical pharmacology and therapeutics.

Chicago

Mürdter T E, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching P A, Fehm T, Eichelbaum M, Schwab M and Brauch H. 20110621. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. : Clinical pharmacology and therapeutics.

Harvard

Mürdter T. E., Schroth W., Bacchus-Gerybadze L., Winter S., Heinkele G., Simon W., Fasching P. A., Fehm T., Eichelbaum M., Schwab M. and Brauch H. (20110621). Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. : Clinical pharmacology and therapeutics.

MLA

Mürdter T E, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching P A, Fehm T, Eichelbaum M, Schwab M and Brauch H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. : Clinical pharmacology and therapeutics. 20110621.